These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 28956340

  • 21. Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice.
    Park SM, Chen M, Schmerberg CM, Dulman RS, Rodriguiz RM, Caron MG, Jin J, Wetsel WC.
    Neuropsychopharmacology; 2016 Feb; 41(3):704-15. PubMed ID: 26129680
    [Abstract] [Full Text] [Related]

  • 22. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer HY.
    Behav Brain Res; 2015 May 15; 285():165-75. PubMed ID: 25448429
    [Abstract] [Full Text] [Related]

  • 23. Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways.
    Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X.
    Int J Mol Sci; 2024 Oct 03; 25(19):. PubMed ID: 39408997
    [Abstract] [Full Text] [Related]

  • 24. Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia.
    Kinon BJ, Leucht S, Tamminga C, Breier A, Marcus R, Paul SM.
    J Clin Psychiatry; 2024 Aug 19; 85(3):. PubMed ID: 39196873
    [Abstract] [Full Text] [Related]

  • 25. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.
    Paz RD, Tardito S, Atzori M, Tseng KY.
    Eur Neuropsychopharmacol; 2008 Nov 19; 18(11):773-86. PubMed ID: 18650071
    [Abstract] [Full Text] [Related]

  • 26. Antipsychotics in the early stage of development.
    Biedermann F, Fleischhacker WW.
    Curr Opin Psychiatry; 2009 May 19; 22(3):326-30. PubMed ID: 19346948
    [Abstract] [Full Text] [Related]

  • 27. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.
    Encephale; 2001 May 19; 27(1):53-9. PubMed ID: 11294039
    [Abstract] [Full Text] [Related]

  • 28. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M, Correll CU.
    Expert Rev Clin Pharmacol; 2015 May 19; 8(3):335-52. PubMed ID: 25916667
    [Abstract] [Full Text] [Related]

  • 29. Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole.
    Topolov MK, Getova DP.
    Folia Med (Plovdiv); 2016 Mar 01; 58(1):12-8. PubMed ID: 27383873
    [Abstract] [Full Text] [Related]

  • 30. Challenges and opportunities for the development of new antipsychotic drugs.
    Forray C, Buller R.
    Biochem Pharmacol; 2017 Nov 01; 143():10-24. PubMed ID: 28522405
    [Abstract] [Full Text] [Related]

  • 31. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
    Abekawa T, Ito K, Koyama T.
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec 01; 374(3):177-93. PubMed ID: 17103144
    [Abstract] [Full Text] [Related]

  • 32. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies.
    Abi-Dargham A, Laruelle M.
    Eur Psychiatry; 2005 Jan 01; 20(1):15-27. PubMed ID: 15642439
    [Abstract] [Full Text] [Related]

  • 33. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M, Czyrak A, Wedzony K.
    Psychiatr Pol; 2000 Jan 01; 34(4):607-21. PubMed ID: 11059260
    [Abstract] [Full Text] [Related]

  • 34. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T, Mouri A, Murai R, Noda Y.
    Ann N Y Acad Sci; 2006 Nov 01; 1086():160-8. PubMed ID: 17185514
    [Abstract] [Full Text] [Related]

  • 35. Biological perspectives: the role of glutamate in schizophrenia and its treatment.
    Steele D, Moore RL, Swan NA, Grant JS, Keltner NL.
    Perspect Psychiatr Care; 2012 Jul 01; 48(3):125-8. PubMed ID: 22724397
    [Abstract] [Full Text] [Related]

  • 36. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E, Chouinard S, Boulay LJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb 01; 29(2):219-32. PubMed ID: 15694228
    [Abstract] [Full Text] [Related]

  • 37. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
    Balu DT, Coyle JT.
    Curr Opin Pharmacol; 2015 Feb 01; 20():109-15. PubMed ID: 25540902
    [Abstract] [Full Text] [Related]

  • 38. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J.
    Encephale; 2009 Feb 01; 35(1):66-72. PubMed ID: 19250996
    [Abstract] [Full Text] [Related]

  • 39. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
    Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R.
    Psychopharmacology (Berl); 2003 Sep 01; 169(3-4):215-33. PubMed ID: 12955285
    [Abstract] [Full Text] [Related]

  • 40. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S.
    Neuropsychopharmacology; 2007 Jun 01; 32(6):1209-15. PubMed ID: 17077809
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.